Plain-English translation of NCT06623461 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Melanoma research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether adding for fecal microbiota transplantation (a treatment that uses beneficial bacteria from the gut) alongside standard immunotherapy works better than immunotherapy alone for advanced melanoma. The trial compares two groups: one receiving only standard immunotherapy drugs, and another receiving the medication plus immunotherapy. Researchers believe that the gut bacteria treatment might help the immune system work more effectively against melanoma.
Standard immunotherapy has helped many melanoma patients, but it doesn't work for everyone. This trial exists because early research suggests that this medication—which introduces beneficial bacteria into the gut—might boost the immune system's ability to fight cancer cells, potentially helping more patients respond to treatment.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups. Both groups receive standard immunotherapy drugs chosen by your doctor before you join the study. The other group also receives bowel preparation followed by a single dose of the medication in capsule form. You will provide blood and stool samples for testing, and your tumor tissue will be analyzed to help researchers understand how the treatment works. You'll need to start immunotherapy within two weeks of enrollment and attend regular follow-up visits to monitor your progress and any side effects.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Canada